Industry News



Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info



Vanta Bioscience’s Chennai Preclinical Research Facility Gets GLP Accreditation

Vanta Bioscience, a US-owned and operated preclinical Contract Research Organization (CRO), has received Good Laboratory Practice (GLP) accreditation for its toxicology facility in Chennai from the National GLP Compliance Monitoring Authority (NGCMA), a branch within the Government of India, after successfully clearing preliminary and final audits.

NGCMA administers the GLP programme in India as a member state and participant in the principles of GLP charter of the Organization for Economic Co-operation and Development (OECD). As a result, data generated at Vanta Bioscience is now recognized by member countries around the world, including: Canada, Germany, Japan, and the US. This certification covers the areas of acute toxicology, genotoxicology, subacute toxicology, subchronic toxicology, chronic toxicology (carcinogenicity), and reproductive toxicology.

GLP refers to a uniform worldwide quality system of management controls for research labs to ensure the consistency, reliability, reproducibility, quality and integrity of the tests performed under the OECD principles of GLP.

Vanta Bioscience is a full service lifescience R&D outsourcing company with research laboratories in Chennai, India, and offices in Brussels, Belgium and West Des Moines, Iowa, US. Complying with OECD GLP, ISO, AAALAC & US FDA GLP (21 CFR Part 58) guidelines, Vanta Bioscience provides a broad and integrated portfolio of services covering pharmacology, safety assessment, chemistry and CMC/clinical consulting and project management.

( Ref: )

Pharmexcil Asks Govt To Hike Reimbursement For Product Registration

Pharmaceutical Export Promotion Council of India (Pharmexcil) has demanded the union Ministry of Commerce and Industry to increase the reimbursement fees provided to the Indian companies for product registration in the US by 50 percent. Through this proposal, the Council aims to safeguard the interest of the Indian companies against the burden of huge user fee that the USFDA is planning to levy from all the companies exporting to the US through its proposed Generic Drug User Fee Act (GDUFA).

Dr. P. V. Appaji, director general (DG), Pharmexcil stressed, “By increasing reimbursement , we hope to provide some kind of relief to all the exporters in the backdrop of this proposed Act. We have initiated to take up this export friendly decision to ensure that no matter what the circumstances the exports are not affected drastically due to this issue.”

He further informed that Pharmexcil is soon planning to take-up this issue with the US government as well so that they can urge them to re-consider their proposal on the fee structure.

( Ref : Chronicle Pharmabiz, July 5, 2012 )

Other News

CDSCO Sets Ambitious Expansion Plan In Capacity Building During 2013-20
Taking A PEEK At New Implants





Back | Back To Top | Previous | Next